Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.

Aug 1, 2025 · On a per share basis, Endo shareholders are entitled to receive approximately $1.31 in cash and 0.2575 of Mallinckrodt shares. Endo shares have ceased trading on the OTCQX.

As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into …

Mar 13, 2025 · Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to separate that …

Jun 9, 2025 · Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement/prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, …

Jun 17, 2025 · Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these …

Oct 9, 2025 · Mallinckrodt and Endo have merged to create a global, scaled, diversified therapeutics leader. Visit our new Investor Relations website at ir.mallinckrodt.com for up-to-date investor …

Endo’s century-long manufacturing legacy encompasses life-saving products and contributions to science and technology. The new 90,000-square-foot facility in Rochester, Michigan builds on this …

Mar 13, 2025 · Endo is providing the following financial guidance for the full year ending December 31, 2025 based on Endo's current views, beliefs, estimates and assumptions.

Jun 13, 2025 · As initially announced on March 13, Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction …